![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 32, 28892-28901, August 9, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Laboratory of Cancer Biology and Molecular Immunology,
Graduate School of Pharmaceutical Sciences, The University of Tokyo,
Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan and the
§ Cancer Center and the Division of Biology, University of
California, San Diego, La Jolla, California 92093-0687
Received for publication, April 18, 2002, and in revised form, May 16, 2002
A novel mouse macrophage galactose-type C-type
lectin 2 (mMGL2) was identified by BLAST analysis of expressed sequence
tags. The sequence of mMGL2 is highly homologous to the mMGL, which should now be called mMGL1. The open reading frame of mMGL2 contains a
sequence corresponding to a type II transmembrane protein with 332 amino acids having a single extracellular C-type lectin domain. The
3'-untranslated region included long terminal repeats of mouse early transposon. The Mgl2 gene was cloned from a
129/SvJ mouse genomic library and sequenced. The gene spans 7,136 base
pairs and consists of 10 exons, which is similar to the genomic
organization of mMGL1. The reverse transcriptase-PCR analysis indicates
that mMGL2 is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner, also very similar to that of mMGL1. The
mMGL2 mRNA was also detected in mMGL1-positive cells, which were
sorted from thioglycollate-induced peritoneal cells with a
mMGL1-specific monoclonal antibody, LOM-8.7. The soluble recombinant proteins of mMGL2 exhibited carbohydrate specificity for Macrophages (MØs)1 and
related cells are widely distributed throughout the body, displaying a
morphological and functional diversity. They are found in the lymphoid
organs, liver, lungs, gastrointestinal tract, central nervous system,
serous cavities, bones, synovia, and skin. Resident MØs mediate
clearance of senescent or apoptotic cells, produce and secrete
cytokines, are involved in hemopoiesis and bone resorption, transport
and present antigens, and regulate neuroendocrine processes. Activated
MØs are recruited to sites of infection, tissue injury, inflammation,
and neoplasia and play crucial roles in tissue repair and pathogenesis
(1).
The distribution and functional heterogeneity of MØs derive in part
from their specialized plasma membrane receptors (2). Cell surface
markers such as F4/80, sialoadhesin, MØ mannose receptor and
scavenger receptor type A have significantly contributed to the current
understanding of MØ ontogeny and function (3). However, in comparison
to other immune cells such as B and T lymphocytes, relatively few
MØ-restricted cell surface molecules have been identified. The
physiological and pathological roles of these putative markers remain unknown.
Protein-carbohydrate interactions serve a variety of functions in the
immune system. A number of lectins (carbohydrate-binding proteins)
mediate both pathogen recognition and cell-to-cell interactions using
structurally related carbohydrate recognition domains (CRDs). One of
the most diversified families of these CRDs is
Ca2+-dependent and termed C-type CRDs (4, 5).
MØs and related cells such as dendritic cells are known to express
several subfamilies of C-type lectins: type 1 multilectins such as MØ
mannose receptor and lectins having type II transmembrane
configurations such as MØ galactose-type (known previously as
galactose/N-acetylgalactosamine-specific) C-type lectin
(MGL). These lectins seem to mediate carbohydrate-specific endocytosis
(6-11). Little is known regarding the expression of selectins, another
subfamily of C-type lectins, in MØs and related cells.
Previously, MGL was cloned from rats, mice, and humans and
characterized. The lectin from mice was shown to have specific affinity
for highly branched N-linked carbohydrate chains with terminal A C-type lectin highly homologous to MGL and expressed mainly on
hepatocytes, the hepatic asialoglycoprotein receptor (ASGR), has two
isomers in mice, rats, and humans, apparently due to recent gene
duplication. Previously, MGL was believed to have a single gene.
Southern blotting analysis supported this notion. However, in this
report, we describe the properties of another novel MØ galactose-type
C-type lectin, mMGL2. As an obvious consequence, the previous mMGL must
now be called mMGL1. These lectins are highly homologous to each other
except in their cytoplasmic domains and CRDs. We found that mMGL2 has a
distinct carbohydrate specificity from mMGL1. These lectins seem to be
expressed on the same cells and therefore seem to function cooperatively.
Cells--
The following cell lines were provided by Cell
Resource Center for Biomedical Research, Institute of Development,
Aging and Cancer Tohoku University, Sendai, Japan: L929, JLS-V9,
EL4, RL
Thioglycollate-induced peritoneal cells (TG-PEC) were obtained from
6-8-week old female C57BL/6J mice from Clea Japan, Inc (Kawasaki,
Japan). These were maintained under pathogen-free conditions. These
mice received 1 ml of 4% thioglycollate broth (Difco, Detroit, MI) by
intraperitoneal injection. Four days later, mice were sacrificed by
neck dislocation, and peritoneal exudate cells were harvested by lavage
with 5 ml of RPMI 1640 media on ice.
TG-PEC were suspended in chilled 0.1% BSA/Dulbecco's modified
phosphate-buffered saline (DPBS: 137 mM NaCl, 13.4 mM KCl, 40.5 mM
Na2HPO4, 7.35 mM
KH2PO4, 0.49 mM MgCl2,
0.905 mM CaCl2) containing phycoerythrin-labeled mAb LOM-14 (reactive with mMGL1 and mMGL2 as
described below) and biotin-labeled mAb LOM-8.7 (reactive with mMGL1)
and then incubated with streptavidin-fluorescein isothiocyanate (Zymed Laboratories Inc., South San Francisco, CA) on
ice. The cells were sorted for the expression of mMGL1 (mAb
LOM-8.7 staining) by Epics Elite (Beckman Coulter).
Mice--
Mgl1 RNA Preparations and RT-PCR Analysis--
Total RNAs were
extracted by using Ultraspec RNA zol (Biotecx, Houston, TX) according
to the manufacturer's instructions. First-strand cDNA synthesis
was carried out using oligo(dT)12-18 and Superscript II
(Invitrogen). The cDNA was used as the template in PCR
reactions using Ampli Taq Gold polymerase (Applied
Biosystems). PCR was performed with specific primers for
mMgl1 (5'-TCTCTGAAAGTGGATGTGGAGG-3', 5'-CACTACCCAGCTCAAACACAATCC-3'), mMgl2
(5'-TCTCTGAAAGTGGATGTGGAGG-3', 5'-GCTATAAGTTGTGGGGAGTGGGC-3'), and
G3pdh (5'-TGAAGGTCGGTGTGAACGGATTTGGC-3', 5'-CATGTAGGCCATGAGGTCCACCAC-3'). The specific primers were designed with Genetyx-Mac (Software Development Co. Ltd., Tokyo, Japan). The
conditions were 94 °C for 30 s, 65 °C for 30 s, and
72 °C for 2 min for 40 cycles. Amplifications of G3pdh
were used as a control for cDNA quantity. The conditions were
94 °C for 30 s, 61 °C for 30 s, and 72 °C for 1 min
for 25 cycles. The PCR products were then separated on 1% agarose
gels, stained with ethidium bromide, and visualized with the Fluor-S
image analyzer (Bio-Rad).
Rapid Amplification of cDNA Ends (RACE)--
The
poly(A)+ RNA from RAW264.7 cells were isolated using a
µMACS mRNA isolation kit (Miltenyi Biotec).
Adapter-ligated cDNA were synthesized using the Marathon cDNA
amplification kit (CLONTECH). To obtain a
full-length cDNA of mMGL2, an antisense primer, AS3 (5'-TCCTCCACATCCACTTTCAGAG-3'), and a sense primer, 3S1
(5'-TTGGAGCGGGAAGAGAAAAACCAG-3'), were designed from the expressed
sequence tag clones for 5'-RACE and 3'-RACE reactions, respectively.
Reactions were incubated at 95 °C for 10 min followed by 43 cycles
at 94 °C for 45 s, 60 °C for 45 s, and 72 °C for 2 min. The resulting 1.5-kbp and 700-bp products were subcloned into the
pGEM-T easy vector (Promega UK, Southampton, UK) and sequenced with the
dye primer method.
Screening of the Genomic Clone Coded the mMgl2 Gene--
A
129/SvJ mouse genomic library (Stratagene; vector Production and Isolation of Soluble mMGL2--
cDNA encoding
mMGL1 and mMGL2 was cloned into pGEM-T easy vector (Promega). The
vector was digested with BamHI and SacI (for mMGL1) or BamHI and NotI (for mMGL2). The
fragments encoding these neck and CRD domains were separated with
agarose gel electrophoresis and inserted into each site of expression
plasmid vector pET-21a (Novagen). The BL21(DE3) cells containing the
plasmid were grown to mid-log phase at 37 °C in 2× TY medium
(1.2 liters) and then treated with isopropyl
Solid Phase Binding Assays--
Absorption of the purified
soluble recombinant mMGL1 or mMGL2 onto enzyme-linked
immunosorbent assay plates (655061, Greiner) was carried out by adding
100 µl of solution (3 µg/ml in DPBS) to each well and incubating
the plates for 18 h at 4 °C. After blocking of the wells using
3% bovine serum albumin (BSA) in DPBS for 2 h at room
temperature, 150 µl solution of biotinylated soluble polyacrylamide
with attached mono- or oligosaccharides (GlycoTech, Rockville, MD) or
hybridoma culture supernatant, diluted into varying concentrations with
DPBS containing 3% BSA, were added to each well. After incubation for
2 h at 4 °C (at room temperature for mAb reactions), the wells
were washed three times with DPBS to remove unbound materials, and then
100 µl of HRP-conjugated streptavidin solution (1.25 µg/ml in DPBS)
or HRP-conjugated goat anti-rat IgG (H + L) solution (0.375 µg/ml in
DPBS) for rat mAbs was added to detect bound materials. After
incubation for 1 h at room temperature, the wells were washed
three times with DPBS. Subsequently, 100 µl of 1 mM 2, 2'-amino-bis(3-ethylbenzthiazoline-6-sulfonic acid) ammonium (ABTS)
solution containing 0.34% H2O2 in 0.1 M sodium citrate buffer (pH 4.3) was added, and the
absorbance was measured at 405 nm on a microplate reader (25).
To determine pH dependence of the binding of mMGL1 and mMGL2, the
incubation conditions were modified as follows. After the blocking
buffer was removed, the wells were washed three times with DPBS.
Aliquots (50 µl) of biotinylated soluble polyacrylamide in 2×
incubation buffer (274 mM NaCl, 26.8 mM KCl,
0.98 mM MgCl2, 1.810 mM
CaCl2, 2% BSA) were mixed with equal volumes of 2× pH buffer (50 mM sodium acetate buffer at pH 4.5-6.0, 50 mM MES buffer at pH 6.0-7.0, 50 mM Tris-HCl
buffer at pH 7.0-8.0) and transferred to each well. Incubation was
performed at 4 °C for 1.5 h. The wells were emptied and washed
three times with DPBST (DPBS containing 0.1% Tween 20) and 100 µl of
HRP-conjugated streptavidin solution (Zymed Laboratories
Inc., 1000 × in DPBS containing 1% BSA) was added and
incubated for 1 h at 4 °C. The wells were emptied and washed
three times with DPBST, and then 100 µl of ABTS solution containing
0.034% H2O2 (1 mM ABTS dissolved
in 0.1 M sodium citrate buffer, pH 4.2) was added, and
absorbance at 405 nm was determined.
Immunohistochemical Staining--
MGL-positive cells were
immunohistochemically detected in the skin as described previously
(19). In brief, skin samples freshly prepared from
Mgl1 Cloning of a Novel Macrophage C-type Lectin--
We found four
clones (GenBankTM accession numbers AA511511, AA537107,
AA671707, and AA498512) similar to mMGL (mMGL1, GenBankTM accession number S36676) and hMGL (HML-2,
GenBankTM accession number D50532) in the data base of
mouse expressed sequence tag. To obtain the full sequences of a novel
C-type lectin, 5'- and 3'-RACE reactions were performed using mRNA
from RAW264.7 cells as a template and with specific primers designed to
match these expressed sequence tag clones. The full-length cDNA was prepared by RT-PCR of poly(A)+ RNA from RAW264.7 cells. The obtained full-length cDNA (GenBankTM accession number AY103461)
encodes an open reading frame of 996 base pairs, predicting a protein
of 332 amino acid residues (38,067 Da), which we subsequently termed
mMGL2 (Fig. 1). The 3'-untranscription
region has a sequence of long terminal repeat (LTR) of mouse early
transposon (26, 27). The nucleotide sequence of mMGL2 has 79.0 and
54.9% identity with that of mMGL1 and hMGL (HML-2), respectively. The
amino acid sequence of mMGL2 has 91.5 and 51.8% identity with that of
mMGL1 and hMGL (HML-2), respectively. The neck domain is highly
homologous to mMGL1 at 95.3%. Only five residues (Ile-87, Asn-108,
Leu-144, Glu-166, and Thr-167) were different in the neck domain from
Arg-78 to Gly-183. Amino acids within the CRD (corresponding to exons
8-10), particularly those corresponding to the last exon (exon 10),
showed differences between mMGL1 and mMGL2. In the sequence of
cytoplasmic domain (corresponding to exon 2), mMGL2 has a putative
internalization signal (YXX Genomic Structure and Chromosome Location of mMGL2--
Screening
of a 129/SvJ mouse genomic library led to the isolation of three
clones. Two clones (termed 92b and 41b) were included in the
Mgl (Mgl1) gene (GenBankTM accession
number AF132744) (29), but the other clone (termed 41a) was included in
the Mgl2 gene, confirmed by PCR using primers of mMGL2. The
latter gene spans 7136 bp, consists of 10 exons, and is similar to
Mgl (Mgl1) in genomic organization (Fig.
2A). The GenBankTM
accession number of the Mgl2 gene is AY103462. The
intron/exon boundaries were defined using DNA sequencing. All
splice sites conform to the AG/GT rule (Table
I). This clone contains 5'-upstream sequences. To identify the promoter sequences of the Mgl2
gene, transcription factor binding site consensus sequences were
searched using the transcription factor data base
(www.cbrc.jp/research/db/TFSEARCH.html). The promoter lacks a classical
TATA box but contains several binding sites for other transcription
factors, C/EBP
We identified the BAC clone RPCI-23-172M21, which coded the
Mgl2, Asgr1, and Asgr2 genes. The
other clone RPCI-23-198E14 encodes the Mgl2 and
Mgl1 genes. These BAC clones have been constructed from the
genomic DNA of female C57BL/6J mice. Therefore, these four C-type
lectin genes should be located within about 150 kb on mouse chromosome
11 (Fig. 2B).
Reactivity with Monoclonal Antibodies--
Previously, we have
obtained mAbs specific for MGL1 using purified mMGL (likely to be a
mixture of mMGL1 and mMGL2) and recombinant MGL1 as immunogens.
Screening to obtain specific monoclonal antibodies was performed
previously with recombinant mMGL1 (25). The antibodies are mAb LOM-4.7,
mAb LOM-8.2, mAb LOM-8.7, all shown to have blocking activity, mAb
LOM-11, shown to recognize the ligand-induced binding site, and a
non-blocking mAb LOM-14 (25, 30). As shown in Fig.
3, mAb LOM-4.7, mAb LOM-8.2, mAb LOM-8.7,
and mAb LOM-11 were shown to be specific for MGL1. LOM-14 bound to both
MGL1 and MGL2 (Fig. 3). These results suggested that the most diverse region of these lectins was the ligand binding site.
Distribution of mMGL2 mRNA in Tissue and Cells--
As a
means of testing the expression profiles of this putative gene and
mMgl1, RT-PCR analysis was performed on 10 mouse cell lines
including L929 (fibroblast line), JLS-V9 (fibroblast-like bone
marrow-derived cell line), EL4 (thymoma cell line), RL mMGL2-positive Cells in Tissue Sections from Mgl1 Carbohydrate Specificity of mMGL2--
A variety of biotin-labeled
soluble polyacrylamides with mono- or oligosaccharides were applied to
determine the carbohydrate specificity of mMGL1 and mMGL2 (Fig.
6). The carbohydrates tested are listed
in the figure. The recombinant form of mMGL1 had the highest affinity
with Lex residues among all carbohydrate-modified
polyacrylamides tested. mMGL2 showed a very low affinity with
LeX but showed the highest affinity with pH-dependent Binding of Ligands to
mMGL--
Enzyme-linked immunosorbent assays were performed under
various pH conditions to determine the binding of soluble
polyacrylamides with LeX residues or In the present study, we found a novel MØ C-type lectin, mMGL2,
and characterized its genomic structure, expression patterns, and
carbohydrate specificity. The Mgl2 gene spans 7136 bp and consists of 10 exons, which is a similar genomic organization to that
of the Mgl gene now renamed the Mgl1 gene. We
reported that the Mgl1 gene linked to Trp53 and
is located 1.8 ± 1.2 cM distal to D11Mit5 and 1.8 ± 1.2 cM proximal to Htt on mouse chromosome 11. Using a
panel of DNA samples from two parental mice, C3H/HeJ-gld and
(C3H/HeJ-gld × Mus spretus) F1 were
digested with various restriction endonucleases and hybridized with a
mMGL1 cDNA probe to determine the restriction fragment length
polymorphism and to allow haplotype analyses (29). The hepatic
asialoglycoprotein receptor genes (Asgr1 and
Asgr2) were also known to be linked to Trp53
(32). We found BAC clones, which included these two C-type lectins.
These results indicate that the highly homologous Mgl2 gene
is linked within about 50 kb. Their homology and close genomic
localization indicate that the original gene was duplicated recently.
The human MGL (HML-2) gene was mapped in
chromosome 17p and linked to ASGR1 and ASGR2.
These results show that there is a cluster of type 2 C-type lectin
genes on mouse chromosome 11 and on human 17p12-13. Likewise, the
natural killer gene complex resided on mouse chromosome 6 and on human
12p (33, 34).
Although there was a high degree of sequence homology between mMGL1 and
mMGL2, the sequences corresponding to cytoplasmic and CRD showed
differences, suggesting that cytoplasmic tail associations and the
carbohydrate recognitions are unique between mMGL1 and mMGL2. We showed
that recombinant mMGL1 bound soluble polyacrylamides containing
Lex oligosaccharides. mMGL2 had affinity with
polyacrylamides containing There is a possibility that mMGL1 and -2 form heterooligomers. These
lectins are known to form trimeric structures through the interactions
of the neck domain in a similar manner to that of ASGRs. ASGRs are
abundantly expressed on the sinusoidal surface of hepatic parenchymal
cells (37, 38). Its primary role is the removal and degradation of
desialylated glycoproteins from circulation. High affinity binding
requires the receptor to be assembled as a heterooligomer consisting of
two highly homologous subunits, termed hepatic lectin 1 and 2 (39).
Experiments with recombinant rat hepatic lectins suggested that the
binding properties of the major subunit (RHL-1) and the minor subunit
(RHL-2/-3) were optimized for different ligands (40). In the case of
mMGL1 and -2, the recombinant form corresponding to each one showed affinity with different carbohydrates, indicating that heterooligomer formation was not required for their carbohydrate recognition. However,
these lectins were likely to be expressed on the same cells at the
single cell level and cooperatively functioned to recognize and uptake
extracellular molecules.
mMGL1-positive cells are abundant in connective tissues throughout the
body (19). mMGL1 was shown to be expressed on the surfaces of bone
marrow-derived immature dendritic cells (21). hMGL is also shown to be
expressed on monocyte-derived immature dendritic cells and
monocyte-derived immature MØs in humans (41). We have shown that
mMGL1-positive cells migrate from dermis to regional lymph nodes during
the sensitization phase of contact hypersensitivity (42). The migration
was initiated by cytokine-mediated release of mMGL1-positive cells from
dermis (42-44). The cells homed to the boundary of the T-cell area in
the regional lymph nodes, and the prevention of migration seemed to
interfere with sensitization. Involvement of coordinated functions of
mMGL1 and -2 in such pathogenic processes should be the most important
subject of future investigations.
*
This work was supported by grants-in-aid from the
Ministry of Education, Science, Sports and Culture of Japan
(09254101, 11557180, 11672162, and 12307054), from the Research
Association for Biotechnology, Special Coordination Funds for Promoting
Science and Technology of the Ministry of Education, Culture, Sports,
Science and Technology, and from the Program for Promotion of
Basic Research Activities for Innovative Biosciences.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the DDBJ/GenBankTM/EBI Data Bank with accession number(s) AY103461, AY103462.
¶
To whom correspondence should be addressed. Tel.:
813-5841-4870; Fax: 813-5841-4879; E-mail:
irimura@mol.f.u-tokyo.ac.jp.
Published, JBC Papers in Press, May 16, 2002, DOI 10.1074/jbc.M203774200
The abbreviations used are:
MØ, macrophage;
ABTS, 2,2'-amino-bis(3-ethylbenzthiazoline-6-sulfonic acid);
ASGR, hepatic asialoglycoprotein receptor;
BAC, bacterial
artificial chromosome;
BSA, bovine serum albumin;
CRD, carbohydrate-recognition domain;
DPBS, Dulbecco's
phosphate-buffered saline;
HRP, horseradish peroxidase;
MGL, macrophage
galactose-type C-type lectin;
RHL, rat hepatic lectin;
RT, reverse
transcriptase;
TG-PEC, thioglycollate-induced peritoneal cells;
RACE, rapid amplification of cDNA ends;
STAT, signal transducers and
activators of transcription;
mAb, monoclonal antibody;
MES, 4-morpholineethanesulfonic acid;
MOPS, 4-morpholinepropanesulfonic
acid;
h, human;
m, mouse;
r, rat.
Molecular Cloning and Characterization of a Novel Mouse
Macrophage C-type Lectin, mMGL2, Which Has a Distinct Carbohydrate
Specificity from mMGL1*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
- and
-GalNAc-conjugated soluble polyacrylamides, whereas mMGL1
preferentially bound Lewis X-conjugated soluble polyacrylamides
in solid phase assays. These two lectins may function cooperatively as
recognition and endocytic molecules on macrophages and related cells.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosyl groups and glycopeptides carrying three consecutive
-GalNAc-Ser/Thr (Tn-antigens) (12). A human MGL was also
shown to have affinity for glycopeptides carrying three consecutive
Tn-antigens (13). Surface plasmon resonance revealed that affinity of
recombinant hMGL for immobilized glycopeptides increased in parallel
with the number of GalNAc residues (14). Tn-antigen was known as a
marker of malignant cells, and MGL was shown to play a role as a
recognition molecule on MØs for tumor cells (15-17).
Immunohistochemical localization of mouse MGL (mMGL) with specific
monoclonal antibodies revealed that this lectin has a strong
association with MØs residing in connective tissue and those
infiltrated into tumor tissues (18-20). Recent studies demonstrated
that this lectin is also expressed on the surface of immature dendritic
cells and is involved in the uptake of glycosylated antigens in mice
and humans (21, 22).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1, YAC-1, BCL1-B20, P815, P388, and M1 cells. RAW264.7 cells
were purchased from ATCC. All cells were cultured in RPMI 1640 media with 10% fetal calf serum at 37 °C with 5% CO2.
/
mice were prepared in
Hedrick's laboratory at the University of California, San
Diego, CA. The details will be published in a separate study (23).
FIXII) was
screened with the complete mMGL1 cDNA coding sequence labeled by
random priming with 32P by plaque hybridization. The
fragments of positive clones were subcloned into pBluescript SK(+)
(Stratagene). These clones were sequenced with 24 specific primers with
the dye-terminator method. These sequences were assembled and aligned
using Genetyx-Mac.
-D-thiogalactoside at a concentration of 1 mM. After isopropyl
-D-thiogalactopyranoside
induction, the cultured cells were washed with 50 mM
Tris-HCl, pH 8.0, containing 0.15 M NaCl (TBS) and
suspended in TBS containing phenylmethanesulfonyl fluoride. The cell
lysates were prepared by freezing and thawing, and after the addition
of DNase I (final 50 units/ml) and lysozyme (final 0.2 mg/ml), they
were incubated 1 h at 37 °C and then centrifuged at 15,000 × g for 10 min at 4 °C. Expressed proteins formed
inclusion bodies. The pellets were washed with TBS containing 0.5%
Triton X-100 and 10 mM EDTA and then with H2O.
The washed pellets were solubilized with 2 M
NH4OH (20 ml) and then added to 25 mM MOPS buffer, pH 7.0, containing 2 mM glutathione, reduced form,
0.2 mM glutathione, oxidized form, 20 mM
CaCl2, 0.5 M NaCl, and 0.02% NaN3
(20 ml). These solutions were then dialyzed against 25 mM MOPS buffer, pH 7.0, containing 20 mM CaCl2,
0.5 M NaCl, and 0.02% NaN3. Soluble
recombinant mMGL1 and mMGL2 were purified by affinity chromatography on
a column of galactose-Sepharose 4B, as described previously (24).
/
mice and their littermates were
embedded in OCT compound (Miles, Elkhart, IN) and frozen in a liquid
nitrogen bath. Cryostat sections (10 µm thick) were picked up on
poly-L-lysine-coated slides and fixed in ice-cold acetone
for 10 min. Nonspecific bindings were blocked using a blocking solution
(2% normal mouse serum and 3% BSA in DPBS) for 10 min. The sections
were treated with the first antibodies for 1 h and then treated
with biotinylated mAb mouse anti-rat
and
(

![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) (28), which is also
present in mMGL1, and an insertion of extra 14 amino acid residues. A
consensus sequence for polyadenylation signal is present in nucleotides
1467-1472 followed by a poly(A) tail. There are two potential
N-glycosylation sites (Fig. 1), both in mMGL1 and -2.

View larger version (58K):
[in a new window]
Fig. 1.
The nucleotide sequence of the mMGL2
cDNA. A, the nucleotide sequence of the mMGL2 cDNA
and its deduced amino acid sequence. The putative transmembrane domain
is underlined. The poly-A addition signal is
underlined with a broken line. The potential
N-glycosylation site is underlined with a
wavy line. The putative internalization signal is
boxed. B, amino acid sequences of mMGL1 and
mMGL2. Asterisks mark the amino acid residues conserved in
both lectins. Arrows indicate boundaries of exons.
, CF1/, AML-1, c-Ets, PU.1, c-Rel, Oct-1,
Lyf-1, AP-1, GATAs, and STATs. These features are almost identical to
that of the 5'-flanking motifs of the Mgl1 gene. These are
the sites found upstream of genes expressed preferentially by cells of
monocyte/MØ lineages (Fig. 2C).

View larger version (34K):
[in a new window]
Fig. 2.
Genomic structure of Mgl2
gene. As shown in A, the gene spans 7136 bp and
consists of 10 exons and is a similar to Mgl1 in
genomic organization. The untranslated regions are shown as
closed boxes, and the coding regions are shown as
hatched boxes. The initiation codon is within the second
exon. B, the linkage of BAC clones. We identified the BAC
clone RPCI-23-172M21, which encodes the Mgl2,
Asgr1, and Asgr2 genes. RPCI-23-198E14 encodes
Mgl2 and Mgl1. C, the promoter
sequences of Mgl2 gene. Transcription factor binding site
consensus sequences were searched using the transcription factor data
base (www.cbrc.jp/ research/db/TFSEARCH.html).
Splice junction sequences, exon sizes, and estimated intron sizes of
the mouse Mgl2 gene

View larger version (23K):
[in a new window]
Fig. 3.
Binding of mAbs to the recombinant mMGL1 and
mMGL2. The binding of mAbs LOM-4.7, LOM-8.2, LOM-8.7, LOM-11, and
LOM-14 to the immobilized recombinant mMGL1 (A) and mMGL2
(B) was measured according to mAb concentration. The binding
of mAbs was detected using HRP-conjugated goat mAbs specific for rat
IgG (H + L). Absorbance at 405 nm was measured on a microplate reader.
The values represent means of triplicate determinations, and the
error bars indicate S.D.
1 (lymphoma
cell line), YAC-1 (lymphoma cell line), BCL1-B20 (malignant B cells),
P815 (mastocytoma cells), P388 (MØ-like lymphoid cell line), M1
(myeloblastic leukemia cells), and RAW264.7 (MØ-like cell line). The
644-bp bands indicating mMgl2 were found only in the cell
lines P388 and RAW264.7 (Fig.
4A). These cell lines were
also high expressers of mMgl1. To assess the expression
patterns of mMgl1 and mMgl2 in vivo,
RT-PCR analysis was conducted on RNA isolated from 13 different normal
mouse tissues and embryos (Fig. 4B). These genes were
expressed almost throughout the body, and the apparent relative
intensities among different organs were similar between
mMgl1 and mMgl2. To assess whether the expression levels of these genes correspond at single cell levels, TG-PEC were
sorted for the binding of mAb LOM-8.7, an mAb specific for mMGL1, and
then reacted with mAb LOM-14 reactive with both mMGL1 and mMGL2. As
shown in Fig. 4C, cells strongly reactive with mAb LOM-8.7
were also reactive with mAb LOM-14. The ratios of expressed mRNAs
corresponding to mMgl1 and mMgl2 shown by RT-PCR
analysis were almost identical when unsorted mAb LOM-8.7-positive and
mAb LOM-8.7-negative cells were compared. These results indicate that the mMgl1-positive cells also express the mMgl2
mRNA.

View larger version (35K):
[in a new window]
Fig. 4.
RT-PCR analysis of mMGL1 and mMGL2 mRNA
expression in cells and tissue. A, the cDNA was
prepared from mouse cell lines (L929, JLS-V9, EL4, RL
1, YAC-1,
BCL1-B20, P815, P388, RAW264.7, and M1). B, tissue cDNA
(CLONTECH) was used after normalizing the relative
amounts according to the levels of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA. C, TG-PEC were
analyzed for the binding of mAbs LOM-14 and LOM-8.7. The cells highly
or poorly reactive with mAb LOM-8.7 were separated and tested for mAb
LOM-14 binding by flow cytometry. cDNA was prepared from the sorted
cells, and RT-PCR analysis was performed. The PCR products were then
separated on 1% agarose gels, stained with ethidium bromide, and
visualized with the image analyzer. The ratios of band intensity of PCR
products were measured. The panels represent a typical result of two
separate experiments including cell fractionations. The results of
these two separate experiments were almost identical.
/
Mice--
Frozen sections of skins from
Mgl1
/
mice were stained with mAb LOM-8.7 and
mAb LOM-14 (Fig. 5). The results revealed
that Mgl1
/
mice expressed epitopes reactive
with mAb LOM-14 at lower levels than Mgl1+/
mice but not with mAb LOM-8.7. These epitopes are likely to represent mMGL2. The subcellular localization of the mAb LOM-14 staining in
Mgl1
/
mice did not appear to be distinct
from that of mAb LOM-8.7 staining in
Mgl1+/
mice.

View larger version (103K):
[in a new window]
Fig. 5.
Distribution of cells expressing mMGL1 and
mMGL2 in skins. Frozen sections of skins from
Mgl1
/
and Mgl1+/
mice were stained with mAb LOM-8.7 (specific for mMGL1) and mAb LOM-14
(cross-reactive between mMGL1 and mMGL2).
-linked GalNAc
residues (Fig. 6). The bindings were inhibited with 5 mM
EDTA (data not shown).

View larger version (29K):
[in a new window]
Fig. 6.
Carbohydrate specificity of recombinant mMGL1
and mMGL2. Binding of biotin-labeled soluble
polyacrylamides containing mono- or oligosaccharides to immobilized
recombinant mMGL1 (A and C) and mMGL2
(B and D). Amounts of bound polymers incubated at
various concentrations were quantified using HRP-conjugated
streptavidin. ABTS was used as a substrate, and absorbance at 405 nm
was measured on a microplate reader. The panels represent a typical
result of three separate determinations, which showed almost identical
results. Each assay was performed in duplicate, and the mean value is
shown.
-GalNAc residues to
immobilized recombinant mMGL1 or mMGL2, respectively. Under a
Ca2+ concentration similar to that found in extracellular
fluids (0.905 mM), the binding decreased when pH was
lowered from extracellular (pH 7.3) to endosomal (pH 5.4). The profiles
of the pH-dependent binding were similar to that observed
with intact hepatic asialoglycoprotein receptors (31). The pH value of
a half-maximal ligand binding, designated as
pHB, was 5.5 for MGL1 and 5.7 for MGL2 (Fig.
7).

View larger version (15K):
[in a new window]
Fig. 7.
Effects of pH on binding of recombinant mMGL1
and mMGL2. The binding of biotin-labeled soluble polyacrylamides
(0.22 µg/ml Lex polyacrylamide or 0.67 µg/µl
-GalNAc polyacrylamide) to the immobilized recombinant mMGL1
(A) or mMGL2 (B) was determined under varied pH
conditions. The assays were performed in the presence of 0.905 mM CaCl2. The values obtained in different
buffers (25 mM sodium acetate buffer for pH 4.5-6.0, 25 mM MES buffer for pH 6.0-7.0, 25 mM Tris-HCl
buffer for pH 7.0-8.0). The panels represent a typical result of two
separate determinations, which showed almost identical results. The
values represent means of duplicate determinations.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
- or
-GalNAc. It has been believed
that C-type lectins contain a peptide segment that corresponds to the
carbohydrate binding specificity within the CRD and that the sequence
in Gal and GalNAc-binding lectins, such as ASGRs, is QPD. In contrast,
the sequence in mannose-, fucose-, and GlcNAc specific lectins, such as
serum mannose-binding proteins, was EPN. The sequence in both mMGL1 and
-2 was QPD. However, it was obvious from our results that their fine
specificities depended on other amino acids in the CRD (Figs. 6 and
8). Some of the amino acid residues
important in the carbohydrate recognitions were conserved in mMGL1,
mMGL2, hMGL, RHL-1 and -2, mASGR-1, and hASGR-1. Crystallographic
determination of the structure of human ASGR-1 revealed amino acid
residues important in sugar binding (35). Furthermore, rat hepatic
asialoglycoprotein receptor was subjected to site-directed mutation. As
a result, the pH dependence of ligand binding was shown to be mediated
by His-256, Asp-266, and Arg-270 (36). Because these residues are also
conserved in mMGL1 and -2, they should also be responsible for their pH dependence (Fig. 8). Amino acid residues responsible for the
differential carbohydrate specificity between mMGL1 and -2 and other
members of the C-type lectin family and the phylogeny of these lectins (Fig. 8) are yet to be elucidated.

View larger version (55K):
[in a new window]
Fig. 8.
Comparison of the amino acid sequences of the
CRD of C-type lectins. A, multialignment of the CRD
sequences of C-type lectins. B, evolutionary tree of
sequence of CRD of C-type lectins. Abbreviations used in this figure
are: MHL, mouse hepatic lectin; rKCR, rat Kupffer
cell receptor; mKCR, mouse Kupffer cell receptor.
![]()
FOOTNOTES
Present address: Dept. of Applied Biological Chemistry, Graduate
School of Agricultural and Life Sciences, The University of Tokyo,
Tokyo, 113-8657, Japan.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Lewis, C.,
and McGee, J. O. D.
(1992)
The Macrophage: The Natural Immune System
, pp. 1-413, IRL Press at Oxford University Press, Oxford
2.
Feizi, T.
(2000)
Immunol. Rev.
173,
79-88[CrossRef][Medline]
[Order article via Infotrieve]
3.
McKnight, A. J.,
and Gordon, S.
(1998)
Adv. Immunol.
68,
271-314[Medline]
[Order article via Infotrieve]
4.
Linehan, S. A.,
Martinez-Pomares, L.,
and Gordon, S.
(2000)
Microbes Infect.
2,
279-288[CrossRef][Medline]
[Order article via Infotrieve]
5.
Weis, W. I.,
Taylor, M. E.,
and Drickamer, K.
(1998)
Immunol. Rev.
163,
19-34[CrossRef][Medline]
[Order article via Infotrieve]
6.
Stahl, P. D.,
and Ezekowitz, R. A.
(1998)
Curr. Opin. Immunol.
10,
50-55[CrossRef][Medline]
[Order article via Infotrieve]
7.
Liu, Y.,
Chirino, A. J.,
Misulovin, Z.,
Leteux, C.,
Feizi, T.,
Nussenzweig, M. C.,
and Bjorkman, P. J.
(2000)
J. Exp. Med.
191,
1105-1116 8.
Leteux, C.,
Chai, W.,
Loveless, R. W.,
Yuen, C. T.,
Uhlin-Hansen, L.,
Combarnous, Y.,
Jankovic, M.,
Maric, S. C.,
Misulovin, Z.,
Nussenzweig, M. C.,
and Ten, F.
(2000)
J. Exp. Med.
191,
1117-1126 9.
Ozaki, K., Ii, M.,
Itoh, N.,
and Kawasaki, T.
(1992)
J. Biol. Chem.
267,
9229-9235 10.
Kawakami, K.,
Yamamoto, K.,
Toyoshima, S.,
Osawa, T.,
and Irimura, T.
(1994)
Jpn. J. Cancer Res.
85,
744-749[CrossRef][Medline]
[Order article via Infotrieve]
11.
Valladeau, J.,
Duvert-Frances, V.,
Pin, J. J.,
Kleijmeer, M. J.,
Ait-Yahia, S.,
Ravel, O.,
Vincent, C.,
Vega, F., Jr.,
Helms, A.,
Gorman, D.,
Zurawski, S. M.,
Zurawski, G.,
Ford, J.,
and Saeland, S.
(2001)
J. Immunol.
167,
5767-5774 12.
Yamamoto, K.,
Ishida, C.,
Shinohara, Y.,
Hasegawa, Y.,
Konami, Y.,
Osawa, T.,
and Irimura, T.
(1994)
Biochemistry
33,
8159-8166[CrossRef][Medline]
[Order article via Infotrieve]
13.
Suzuki, N.,
Yamamoto, K.,
Toyoshima, S.,
Osawa, T.,
and Irimura, T.
(1996)
J. Immunol.
156,
128-135[Abstract]
14.
Iida, S.,
Yamamoto, K.,
and Irimura, T.
(1999)
J. Biol. Chem.
274,
10697-10705 15.
Sakamaki, T.,
Imai, Y.,
and Irimura, T.
(1995)
J. Leukocyte Biol.
57,
407-414[Abstract]
16.
Ichii, S.,
Imai, Y.,
and Irimura, T.
(1997)
J. Leukocyte Biol.
62,
761-770[Abstract]
17.
Ichii, S.,
Imai, Y.,
and Irimura, T.
(2000)
Cancer Immunol. Immunother.
49,
1-9[CrossRef][Medline]
[Order article via Infotrieve]
18.
Imai, Y.,
Akimoto, Y.,
Mizuochi, S.,
Kimura, T.,
Hirano, H.,
and Irimura, T.
(1995)
Immunology
86,
591-598[Medline]
[Order article via Infotrieve]
19.
Mizuochi, S.,
Akimoto, Y.,
Imai, Y.,
Hirano, H.,
and Irimura, T.
(1997)
Glycobiology
7,
137-146 20.
Mizuochi, S.,
Akimoto, Y.,
Imai, Y.,
Hirano, H.,
and Irimura, T.
(1998)
Glycoconj. J.
15,
397-404[CrossRef][Medline]
[Order article via Infotrieve]
21.
Denda-Nagai, K.,
Kubota, N.,
Tsuiji, M.,
Kamata, M.,
and Irimura, T.
(2002)
Glycobiology
12,
443-450 22.
Higashi, N.,
Fujioka, K.,
Denda-Nagai, K.,
Hashimoto, S.,
Nagai, S.,
Sato, T.,
Fujita, Y.,
Morikawa, A.,
Tsuiji, M.,
Miyata-Takeuchi, M.,
Sano, Y.,
Suzuki, N.,
Yamamoto, K.,
Matsushima, K.,
and Irimura, T.
(2002)
J. Biol. Chem.
277,
20686-20693 23.
Onami, T. M,
Lin, M.-Y.,
Page, D. M.,
Reynolds, S. A.,
Katayama, C. D.,
Marth, J. D.,
Irimura, T.,
Varki, A.,
Varki, N.,
and Hedrick, S. M.
(2002)
Mol. Cell. Biol.
22,
5173-5181 24.
Sato, M.,
Kawakami, K.,
Osawa, T.,
and Toyoshima, S.
(1992)
J Biochem. (Tokyo)
111,
331-336 25.
Kimura, T.,
Imai, Y.,
and Irimura, T.
(1995)
J. Biol. Chem.
270,
16056-16062 26.
Tanaka, I.,
and Ishihara, H.
(2001)
Virology
280,
107-114[CrossRef][Medline]
[Order article via Infotrieve]
27.
Mager, D. L.,
and Freeman, J. D.
(2000)
J. Virol.
74,
7221-7229 28.
Trowbridge, I. S.
(1991)
Curr. Opin. Cell Biol.
3,
634-641[CrossRef][Medline]
[Order article via Infotrieve]
29.
Tsuiji, M.,
Fujimori, M.,
Seldin, M. F.,
Taketo, M. M.,
and Irimura, T.
(1999)
Immunogenetics
50,
67-70[CrossRef][Medline]
[Order article via Infotrieve]
30.
Kimura, T.,
Hosoi, T.,
Yamamoto, K.,
Suzuki, N.,
Imai, Y.,
and Irimura, T.
(2000)
Mol. Immunol.
37,
151-160[CrossRef][Medline]
[Order article via Infotrieve]
31.
Hudgin, R. L.,
Pricer, W. E., Jr.,
Ashwell, G.,
Stockert, R. J.,
and Morell, A. G.
(1974)
J Biol. Chem
249,
5536-5543 32.
Blackburn, C. C.,
Griffith, J.,
and Morahan, G.
(1995)
Genomics
26,
308-317[CrossRef][Medline]
[Order article via Infotrieve]
33.
Yokoyama, W. M.,
and Seaman, W. E.
(1993)
Annu. Rev. Immunol.
11,
613-635[Medline]
[Order article via Infotrieve]
34.
Brown, M. G.,
Fulmek, S.,
Matsumoto, K.,
Cho, R.,
Lyons, P. A.,
Levy, E. R.,
Scalzo, A. A.,
and Yokoyama, W. M.
(1997)
Genomics
42,
16-25[CrossRef][Medline]
[Order article via Infotrieve]
35.
Meier, M.,
Bider, M. D.,
Malashkevich, V. N.,
Spiess, M.,
and Burkhard, P.
(2000)
J. Mol. Biol.
300,
857-865[CrossRef][Medline]
[Order article via Infotrieve]
36.
Wragg, S.,
and Drickamer, K.
(1999)
J. Biol. Chem.
274,
35400-35406 37.
Collins, J. C.,
Stockert, R. J.,
and Morell, A. G.
(1984)
Hepatology
4,
80-83[Medline]
[Order article via Infotrieve]
38.
Braun, J. R.,
Willnow, T. E.,
Ishibashi, S.,
Ashwell, G.,
and Herz, J.
(1996)
J. Biol. Chem.
271,
21160-21166 39.
Bider, M. D.,
and Spiess, M.
(1998)
FEBS Lett.
434,
37-41[CrossRef][Medline]
[Order article via Infotrieve]
40.
Ruiz, N. I.,
and Drickamer, K.
(1996)
Glycobiology
6,
551-559 41.
Higashi, N.,
Morikawa, A,
Fujioka, K,
Fujita, Y.,
Sano, Y.,
Miyata-Takeuchi, M.,
Suzuki, N.,
and Irimura, T.
(2002)
Int. Immunol.
14,
545-554 42.
Sato, K.,
Imai, Y.,
and Irimura, T.
(1998)
J. Immunol.
161,
6835-6844 43.
Chun, K. H.,
Imai, Y.,
Higashi, N.,
and Irimura, T.
(2000)
J. Leukocyte Biol.
68,
471-478 44.
Chun, K. H.,
Imai, Y.,
Higashi, N.,
and Irimura, T.
(2000)
Int. Immunol.
12,
1695-1703
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. J. van Vliet, L. C. Paessens, V. C. M. Broks-van den Berg, T. B. H. Geijtenbeek, and Y. van Kooyk The C-Type Lectin Macrophage Galactose-Type Lectin Impedes Migration of Immature APCs J. Immunol., September 1, 2008; 181(5): 3148 - 3155. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sano, K. Usami, R. Izawa, K. Denda-Nagai, N. Higashi, T. Kimura, N. Suzuki, and T. Irimura Properties of Blocking and Non-blocking Monoclonal Antibodies Specific for Human Macrophage Galactose-type C-type Lectin (MGL/ClecSF10A/CD301) J. Biochem., January 1, 2007; 141(1): 127 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dupasquier, P. Stoitzner, H. Wan, D. Cerqueira, A. van Oudenaren, J. S. A. Voerman, K. Denda-Nagai, T. Irimura, G. Raes, N. Romani, et al. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling J. Leukoc. Biol., October 1, 2006; 80(4): 838 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Coombs, M. E. Taylor, and K. Drickamer Two categories of mammalian galactose-binding receptors distinguished by glycan array profiling Glycobiology, August 1, 2006; 16(8): 1C - 7C. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Comelli, S. R. Head, T. Gilmartin, T. Whisenant, S. M. Haslam, S. J. North, N.-K. Wong, T. Kudo, H. Narimatsu, J. D. Esko, et al. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome Glycobiology, February 1, 2006; 16(2): 117 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yuita, M. Tsuiji, Y. Tajika, Y. Matsumoto, K. Hirano, N. Suzuki, and T. Irimura Retardation of removal of radiation-induced apoptotic cells in developing neural tubes in macrophage galactose-type C-type lectin-1-deficient mouse embryos Glycobiology, December 1, 2005; 15(12): 1368 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sato, Y. Imai, N. Higashi, Y. Kumamoto, T. M. Onami, S. M. Hedrick, and T. Irimura Lack of antigen-specific tissue remodeling in mice deficient in the macrophage galactose-type calcium-type lectin 1/CD301a Blood, July 1, 2005; 106(1): 207 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. van Vliet, E. van Liempt, E. Saeland, C. A. Aarnoudse, B. Appelmelk, T. Irimura, T. B. H. Geijtenbeek, O. Blixt, R. Alvarez, I. van Die, et al. Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells Int. Immunol., May 1, 2005; 17(5): 661 - 669. [Abstract] [Full Text] [PDF] |
||||